Welcome to our dedicated page for Atai Beckley news (Ticker: ATAI), a resource for investors and traders seeking the latest updates and insights on Atai Beckley stock.
AtaiBeckley Inc. (NASDAQ: ATAI) is a clinical-stage biopharmaceutical and biotechnology company focused on developing effective, rapid-acting and convenient mental health treatments. The AtaiBeckley news feed on Stock Titan aggregates company announcements, press releases and regulatory disclosures so readers can follow how its clinical programs and corporate developments evolve over time.
News about AtaiBeckley frequently highlights progress across its pipeline of investigational therapies. This includes updates on BPL-003, a mebufotenin (5-MeO-DMT) benzoate nasal spray for treatment-resistant depression and alcohol use disorder; VLS-01, a DMT buccal film for treatment-resistant depression; and EMP-01, an oral R-MDMA formulation for social anxiety disorder. Company releases have covered Phase 2b and open-label extension data for BPL-003, enrollment and site expansion for VLS-01 trials, and exploratory Phase 2a work for EMP-01, as well as regulatory milestones such as FDA Breakthrough Therapy designation for BPL-003.
Investors and observers can also use the ATAI news page to follow corporate events, including the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited to form AtaiBeckley, the company’s redomiciliation to the United States as AtaiBeckley Inc., and its addition to the Nasdaq Biotechnology Index. Filings and press releases related to public offerings, grants from organizations such as the National Institute on Drug Abuse, and intellectual property developments like the U.S. patent granted for EMP-01 are also reflected in the news flow.
By reviewing AtaiBeckley news in one place, readers can track key clinical milestones, financing activities, regulatory designations and strategic transactions that shape the company’s efforts in mental health therapeutics. The ATAI news page can be revisited regularly to see new company communications and related market updates as they are released.
atai Life Sciences has launched TryptageniX, a joint venture with CB Therapeutics, aimed at developing new chemical entities (NCEs) for mental health treatment through bioprospecting and biosynthesis. This initiative is designed to enhance atai's drug development pipeline and expand its intellectual property in both psychedelic and non-psychedelic compounds. TryptageniX will also focus on sustainable manufacturing methods to address the growing mental health crisis. The collaboration is expected to yield innovative solutions for patients while minimizing ecological impacts.
atai Life Sciences (Nasdaq: ATAI) announced an increase in its ownership in COMPASS Pathways from 19.4% to 20.8%, reinforcing its position as the largest shareholder. This move reflects atai's confidence in COMPASS’ recent Phase 2b trial data for COMP360, which showed promising results for treatment-resistant depression (TRD). The trial reported a significant reduction in depression symptoms, indicating potential for COMP360 as a future treatment option. atai emphasizes the importance of COMPASS’ innovative approach in addressing unmet mental health needs.
atai Life Sciences reported positive progress in its therapeutic programs, including encouraging topline results from COMP360’s Phase 2b study for treatment-resistant depression. With cash and equivalents totaling $430.3 million as of September 30, 2021, the company shows strong financial backing after its IPO. Upcoming milestones include Phase 2a data for RL-007 in cognitive impairment expected by the end of Q4 2021. The company's focus on mental health, combined with the recent launch of the atai Impact philanthropic program, positions it for potential growth.
atai Life Sciences N.V. (Nasdaq: ATAI) will host a conference call on November 15, 2021, at 8:30 a.m. ET to discuss its Q3 2021 financial results and provide a business update. Attendees can access the call via dial-in numbers and a dedicated conference ID. Founded in 2018, atai focuses on developing innovative treatments for mental health disorders, including depression and anxiety. The company leverages funding, technology, and regulatory expertise to advance psychedelic therapies and improve treatment options in mental healthcare.
atai Life Sciences N.V. (Nasdaq: ATAI) announced its participation in key investor conferences in November 2021 aimed at transforming mental health treatment. Notable events include the Berenberg US CEO Conference on November 9-10, and the Credit Suisse 30th Annual Healthcare Conference on November 11 at 9:40 a.m. ET, featuring a fireside chat format. The 12th Annual Jefferies London Healthcare Conference is set for November 18, also featuring a fireside chat at 8:00 a.m. ET. Archived webcasts will be available on the company's website.
atai Life Sciences announced promising interim data from its Phase 2a trial of RL-007, which targets Cognitive Impairment Associated with Schizophrenia (CIAS). The results from the initial 8-patient cohort indicate potential cognitive benefits, leading the company to accelerate its development timeline. The trial showcased positive changes in two biomarkers, suggesting improved cognition. The full results are anticipated by year-end 2021. The financial support will expedite planning for the next clinical trial before completing the current one.
atai Life Sciences (Nasdaq: ATAI) has announced the formation of PsyProtix, a new platform focused on precision psychiatry for treatment-resistant depression (TRD) and other mental health conditions. This collaboration with Duke University aims to develop therapeutics that account for patient variability in genes and lifestyle instead of a traditional trial-and-error approach. Over 300 million individuals suffer from major depressive disorder, with TRD presenting significantly higher medical costs. PsyProtix seeks to customize treatments based on metabolomic mechanisms to improve therapeutic outcomes.
DemeRx IB, a platform company of atai Life Sciences (Nasdaq: ATAI), has initiated a Phase 1/2a clinical trial of ibogaine HCl (DMX-1002) for opioid use disorder. The trial has begun dosing with recreational drug users and healthy volunteers in the UK, focusing on safety, tolerability, pharmacokinetics, and efficacy. Previous studies indicate ibogaine's potential for rapid and sustained efficacy in treating opioid dependence. Safety data is expected by early 2022. The trial aims to contribute to existing literature on ibogaine as a treatment option amidst the ongoing opioid crisis.
atai Life Sciences (Nasdaq: ATAI) has amended its loan agreement with IntelGenx Technologies Corp., increasing its loan commitment from US$2.5 million to US$8.5 million to support IntelGenx' graduation to the Toronto Stock Exchange. The additional US$6 million will be allocated in two phases of US$3 million each in January 2022 and January 2023. This move is based on promising early data from ongoing studies. The loan, which matures in January 2024, bears an 8% interest rate, while IntelGenx focuses on developing innovative treatments for mental health disorders.
Perception Neuroscience, a subsidiary of atai, has initiated a Phase 2a clinical study to assess the safety and efficacy of PCN-101 (R-ketamine) for Treatment Resistant Depression (TRD). The trial will enroll 93 patients across 3 arms, with doses of either placebo, 30 mg, or 60 mg of R-ketamine. Patients will be monitored for depressive symptoms over 14 days, with topline data expected by the end of 2022. The study aims to provide insight into R-ketamine's potential as a rapidly-acting antidepressant, addressing the needs of nearly 100 million people affected by TRD.